AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05408156 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Insoles
Description: semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate ethylene vinyl (EVA)
Study NCT04347304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: white chocolate (20 grams) with no polyphenols
Description: subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
Study NCT06382233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of Diagnostic Biomarkers
Description: Urinary single-cell and EVs screening to stage the intrarenal injury and repair processes in UPJO babies and identification of the whole blood gene expression profiling of babies with unilateral UPJO. Data deriving from patients with unilateral UPJO will be compared with data deriving from controls.
Study NCT06527118 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVITIES TO LEARN SELF CARE SKILLS
Description: This activity program, which was prepared to develop self-care skills, aims to teach self-care skills of children with intellectual disabilities by having fun. The program was prepared by the educator and finalized after the approval of expert opinions.
Study NCT06227234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dechoker
Description: Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention.
Study NCT06227234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LifeVac
Description: Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention.
Study NCT06227234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Thrusts
Description: Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention.
Study NCT05455528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: estimated GFR calculation
Description: The estimated GFR is computed with Modification of Diet in Renal Disease (MDRD) formula
Study NCT06374693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: * Pulse width - 25ms~* Frequency - device default (20 or 25Hz)~* Intensity - below pain threshold.~* Frequency - 45 minutes twice daily. On the basis of similarity to other studies, practicalities on the ward and clinical scenario~We have chosen a duration of 5 days based on the usual clinical pathway of inpatient management at the Royal Hallamshire Hospital, and have chosen to deliver the treatment twice daily to optimise the dose. This is a pilot study with feasibility outcomes and as such we will be exploring the feasibility of this treatment regimen.~The Parasym Device will be applied to the left tragus (figure 1) as this is the most common site for tVNS delivery in neurological studies and is associated with few afferents to the heart.
Study NCT05047991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome Injection
Description: Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle
Study NCT05047991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
Study NCT05047991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
Study NCT05047991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle
Study NCT05047991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
Study NCT05047991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
Study NCT06374693 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Vagus Nerve Stimulation
Description: The active intervention will be compared to sham tVNS where the vagal nerve stimulator will be attached to the earlobe instead of the tragus, in keeping with evidence that this does not cause vagus nerve stimulation and is in line with sham methods used in other studies. We do not anticipate that patients will have the intervention long enough to become familiar with the common sensations associated with true tVNS intervention. At the end of the intervention period, participants will be asked if they thought they had received true of sham tVNS to understand the blinding ability of the sham.
Study NCT06713954 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dietary assessment
Description: Dietary intake data will be collected using the Snap-N-Send method, a tool with enhanced validity for assessing athlete total energy intake, where participants will take photographs of their meals and share them via WhatsApp directly with the researcher. Before the study commences, participants will receive standardised instructions on photographing food and adding details in the message such as title, portion sizes and ingredients alongside each photo to enhance data precision. The principal investigator will input these photographs with the added information into Nutritics dietary analysis software, where food weights, portion sizes, and nutritional content will be estimated and calculated. Nutritics will then calculate dependent variables and convert it into a food diary report, aggregating the three days of food diary into average intake.
Study NCT06722131 — intervention group
Intervention type: OTHER
Intervention: Sampling
Description: Additional biological sampling at the same time as routine-care samples taken in the context of the diagnosis of the infectious disease and if planned at one and 12 months of follow-up~* The considered samples are as follows :~  * Blood sample tubes (5 x 5 mL tubes, i.e. 25 mL)~ * Infection site sample if applicable :~* Urine (10 mL)~* Stool (1 mL)~* CSF (1 mL)~* Sputum (1 mL) or bronchoalveolar lavage fluid (10 mL)~* Nasopharyngeal swab (one swab)~* Genital swab (one swab)~* Skin swab (one swab)~* Biopsy (a fragment of a lung, kidney or brain biopsy, if performed)
Study NCT04714710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Potassium Canrenoate
Description: Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room
Study NCT04714710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Sodium Chloride 0.9 %
Description: Administration of IV sodium chloride 0.9% (placebo) in brain-dead donors within 10 hours after the diagnosis of brain death is made and before the departure to the operating room.~Second administration of IV sodium chloride 0.9% (placebo) 6 hours after first administration if the patient is not YET admitted IN the operating room.
Study NCT05933057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
Study NCT05933057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
Study NCT04856488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine-Potassium Iodide 5%-10% Oral and Topical Solution
Description: Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days
Study NCT04732884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartsens, Gelenic AG; with biofeedback
Description: The Smartsens is a CE certified 4-cell load sensor integrated in an insole that can be placed in any orthosis or cast. A threshold (10-50kg) can be defined at which - if higher loads are measured - an audio signal warns the patient of overloading (biofeedback). The device additionally registers loads from 0-100kg continuously.
Study NCT04732884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartsens, Gelenic AG; without biofeedback
Description: Patients will not be warned by an audio signal in case of overloading. The device registers loads from 0-100kg continuously.
Study NCT06533410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that
Description: The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that
Study NCT06509802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Single-session Intervention of Mindset on Intelligence, Failure, and Emotion (We-SMILE)
Description: This study will be a two-arm randomised controlled trial to examine the efficacy of the We-SMILE for pre-practicum social work and/or counselling students by comparing to the We-SMILE intervention group and the no-intervention training-as-usual group.
Study NCT06512753 — intervention group
Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: HCQ (15) is administered orally at a dosage of 400 mg daily.
Study NCT06512753 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: MTX (16) is given at a dose of 15 mg per week, orally or subcutaneously. Additionally, folate supplementation is administered concurrently as part of standard care, with folate 10 mg/week administered 24 hours after MTX intake.
Study NCT04748640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Knife VIM thalamotomy
Description: Ablation of contralateral VIM nucleus of thalamus with GK using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
Study NCT04648267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cast and bolster placement duration
Description: The intervention is increasing the duration of cast and bolster placement on split thickness skin graft sites.
Study NCT04648267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: This will be standard of care - the patient will have his cast and bolster on for 5-7 days
Study NCT06415032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy with Quilting sutures without drain placement
Description: The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After the mastectomy, the skin flaps are sutured onto the pectoral muscle using polyfilament absorbable sutures (e.g. Stratafix PDS® 1 CT needle) placed at 4- to 5-cm intervals in two or three rows depending on the extent of the skin flaps. Care is taken to prevent dimpling of the skin. The axillary region is also approximated. Care is taken to prevent damage to nerves and blood vessels. No suction drains are placed. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference.
Study NCT06415032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mastectomy with Conventional sutures with drain placement
Description: The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After mastectomy no flap fixation is performed. The skin is closed in a conventional manner using an absorbable skin suture. One or two suction drains are placed before skin closure. The drains are placed in the mastectomy gutter lateral to the pectoral muscle and/or in the prepectoral area. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference. Drain output is recorded daily. Drain removal policy varies among participating centres. In some centres drain removal is based on volume of drained fluids while in other centres it depends on the postoperative time
Study NCT05629741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMTX-101
Description: Administered as specified in the treatment arm
Study NCT05629741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study NCT06507709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low volume CBCT
Description: 3-D imaging used during dental practice
Study NCT04747912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: Inotuzumab ozogamicin, sold under the brand name Besponsa, is an anti-cancer drug used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Study NCT04747912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib is a prescription treatment for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
Study NCT04747912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is a steroid that prevents the release of substances in the body that cause inflammation.
Study NCT04747912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia.
Study NCT04747912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine, also known as leurocristine and marketed under the brand name Oncovin among others, is a chemotherapy medication used to treat various types of cancer such as acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small cell lung cancer among others.
Study NCT04747912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: A drug used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Ponatinib blocks BCR-ABL, which may help keep cancer cells from growing and may kill them.
Study NCT04747912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate for Injection
Description: Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia. When given intrathecally, it prevents leukemia cells entering the cerebrospinal fluid (CSF) around the spine and brain. Intrathecal chemotherapy is administered during a procedure called a lumbar puncture or through an ommaya reservoir (shunt).
Study NCT04747912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic Stem Cell Transplantation
Description: A procedure in which a patient receives healthy blood-forming cells (stem cells) from a donor to replace their own stem cells that have been destroyed by treatment with radiation or high doses of chemotherapy. In an allogeneic stem cell transplant, the healthy stem cells may come from the blood or bone marrow of a related donor who is not an identical twin of the patient or from an unrelated donor who is genetically similar to the patient. An allogeneic stem cell transplant is most often used to treat blood cancers, such as leukemia and lymphoma, and certain types of blood or immune system disorders.
Study NCT06487390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Pro training intervention
Description: Training intervention adapted from evidence-based HIV epidemiology, sexual history taking, and PrEP prescription curricula.
Study NCT05662319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fitusiran
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)
Study NCT05662319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotting factor concentrates (CFC) or bypassing agents (BPA)
Description: * Coagulation factor VIII (ATC code: B02BD02)~* Coagulation factor IX (ATC code: B02BD04)~* Coagulation factor VIIa (ATC code: B02BD08)~* Factor VIII inhibitor bypassing activity (ATC code: B02BD03)~Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
Study NCT05662319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin concentrate (ATIIIC)
Description: Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
Study NCT05367895 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use.
Study NCT03127267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib (6.0)
Description: Masitinib (titration to 6.0 mg/kg/day)
Study NCT03127267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole 50 mg tablet, treatment per os
Study NCT05888142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: in clinic pain VR reduction exercises
Description: During the in clinic training phase, participants will use commercially available VR during in clinic VR physical therapy exercises, to help reduce their pain and improve functionality. But this group will not take a VR system home until after completing the in clinic training phase.
Study NCT05888142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In clinic VRpain reduction exercises + VR homeworks
Description: During the training phase, participants will use commercially available VR during in clinic physical therapy exercises, and during the training phase, they will also receive a VR system they take home and will begin VR homeworks during the traininng phase, to help reduce their pain and improve functionality.
Study NCT05928910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmileyScope VR
Description: The SmileyScope Virtual Reality Headset is a VR headset to reduce pain and anxiety undergoing medical procedures. The device comes pre-loaded with a static virtual reality scenario. Participants will use the device in person when coming to clinic during an in-person, one time PNE procedure.
Study NCT05928910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Treatment
Description: Participants in this group will receive standard of care treatment during an in-person, one time PNE procedure.
Study NCT03127267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: Riluzole 50 mg tablet, treatment per os
Study NCT03127267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment per os
Study NCT05396053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy exercises
Description: Three times a week for 12 weeks.
Study NCT05396053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy exercises
Description: Three times a week for 12 weeks.
Study NCT05396053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: Three times a week for 12 weeks.
Study NCT05396053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy
Description: Three times a week for 12 weeks.